EUVIMEDObjevte EUVIMED
Crossref

Calcitonin gene‐related peptide‐targeting therapies are a first‐line option for the prevention of migraine: An American Headache Society position statement update

Andrew C Charles iD, Kathleen B Digre iD, Peter J Goadsby iD, Matthew S Robbins iD, Andrew Hershey iD, American Headache Society

Headache: The Journal of Head and Face Pain · 2024-04 · 64 (4) · 333-341

DOI: 10.1111/head.14692 ↗

At a glance

Journal article in Headache: The Journal of Head and Face Pain, published online on 2024-03-11. Written by Andrew C Charles and 5 co-authors. Institution: Department of Neurology, UCLA Goldberg Migraine Program, Los Angeles, California, USA. Major MEDLINE topics: Calcitonin Gene-Related Peptide, Calcitonin Gene-Related Peptide Receptor Antagonists, Migraine Disorders. Cited 252 times so far (Crossref); 58 references.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Objective

To provide a position statement update from The American Headache Society specifically regarding therapies targeting calcitonin gene‐related peptide (CGRP) for the prevention of migraine.

Background

All migraine preventive therapies previously considered to be first‐line treatments were developed for other indications and adopted later for migraine. Adherence to these therapies is often poor due to issues with efficacy and tolerability. Multiple new migraine‐specific therapies have been developed based on a broad foundation of pre‐clinical and clinical evidence showing that CGRP plays a key role in the pathogenesis of migraine. These CGRP‐targeting therapies have had a transformational impact on the management of migraine but are still not widely considered to be first‐line approaches.

Methods

Evidence regarding migraine preventive therapies including primary and secondary endpoints from randomized placebo‐controlled clinical trials, post hoc analyses and open‐label extensions of these trials, and prospective and retrospective observational studies were collected from a variety of sources including PubMed, Google Scholar, and ClinicalTrials.gov. The results and conclusions based upon these results were reviewed and discussed by the Board of Directors of The American Headache Society to confirm consistency with clinical experience and to achieve consensus.

Results

The evidence for the efficacy, tolerability, and safety of CGRP‐targeting migraine preventive therapies (the monoclonal antibodies: erenumab, fremanezumab, galcanezumab, and eptinezumab, and the gepants: rimegepant and atogepant) is substantial, and vastly exceeds that for any other preventive treatment approach. The evidence remains consistent across different individual CGRP‐targeting treatments and is corroborated by extensive “real‐world” clinical experience. The data indicates that the efficacy and tolerability of CGRP‐targeting therapies are equal to or greater than those of previous first‐line therapies and that serious adverse events associated with CGRP‐targeting therapies are rare.

Conclusion

The CGRP‐targeting therapies should be considered as a first‐line approach for migraine prevention along with previous first‐line treatments without a requirement for prior failure of other classes of migraine preventive treatment.

Subjects

MeSH terms (MEDLINE)

Calcitonin Gene-Related PeptideCalcitonin Gene-Related Peptide Receptor AntagonistsMigraine DisordersHumansAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedConsensus Statements as TopicSocieties, MedicalUnited States

Author keywords

CGRPcalcitonin gene‐related peptide‐targeting therapiesmigraineposition statementprevention

Substances

Antibodies, MonoclonalAntibodies, Monoclonal, HumanizedCalcitonin Gene-Related PeptideCalcitonin Gene-Related Peptide Receptor Antagonistseptinezumaberenumabfremanezumab

Authors and institutions

  • Department of Neurology, UCLA Goldberg Migraine Program, Los Angeles, California, USA.
  • Departments of Neurology and Ophthalmology, University of Utah, Salt Lake City, Utah, USA.
  • King's College London, London, UK.
  • Department of Neurology, Weill Cornell Medical College, New York, New York, USA.
  • Department of Pediatrics and Neurology, University of Cincinnati College of Medicine, Cincinnati, OH, USA.
  • Division of Neurology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.

ORCID profiles: Andrew C Charles, Kathleen B Digre, Peter J Goadsby, Matthew S Robbins, Andrew Hershey

Cite

APA

Charles, A. C., Digre, K. B., Goadsby, P. J., Robbins, M. S., Hershey, A., & American Headache Society (2024). Calcitonin gene‐related peptide‐targeting therapies are a first‐line option for the prevention of migraine: An American Headache Society position statement update. Headache: The Journal of Head and Face Pain, 64(4), 333-341. https://doi.org/10.1111/head.14692

Vancouver

Charles AC, Digre KB, Goadsby PJ, Robbins MS, Hershey A, American Headache Society. Calcitonin gene‐related peptide‐targeting therapies are a first‐line option for the prevention of migraine: An American Headache Society position statement update. Headache: The Journal of Head and Face Pain. 2024;64(4):333-341. doi:10.1111/head.14692

BibTeX
@article{Charles2024,
  author = {Charles, Andrew C and Digre, Kathleen B and Goadsby, Peter J and Robbins, Matthew S and Hershey, Andrew and American Headache Society, American Headache Society},
  title = {Calcitonin gene‐related peptide‐targeting therapies are a first‐line option for the prevention of migraine: An American Headache Society position statement update},
  journal = {Headache: The Journal of Head and Face Pain},
  year = {2024},
  volume = {64},
  number = {4},
  pages = {333--341},
  doi = {10.1111/head.14692}
}
Start for free →